These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 34706253)

  • 1. From Metcalf to myeloproliferative neoplasms - a personal journey.
    Green T
    Exp Hematol; 2022 Jan; 105():2-9. PubMed ID: 34706253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A primer on genomic and epigenomic alterations in the myeloproliferative neoplasms.
    Rampal R; Levine RL
    Best Pract Res Clin Haematol; 2014 Jun; 27(2):83-93. PubMed ID: 25189720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Underlying mechanisms of the JAK2V617F mutation in the pathogenesis of myeloproliferative neoplasms.
    Mullally A
    Pathologe; 2016 Nov; 37(Suppl 2):175-179. PubMed ID: 27796499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The myeloproliferative neoplasms: insights into molecular pathogenesis and changes in WHO classification and criteria for diagnosis.
    Anastasi J
    Hematol Oncol Clin North Am; 2009 Aug; 23(4):693-708. PubMed ID: 19577165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unfolding the Role of Calreticulin in Myeloproliferative Neoplasm Pathogenesis.
    Merlinsky TR; Levine RL; Pronier E
    Clin Cancer Res; 2019 May; 25(10):2956-2962. PubMed ID: 30655313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Italian survey on clinical practice in myeloproliferative neoplasms. A GIMEMA Myeloproliferative Neoplasms Working Party initiative.
    Loscocco GG; Mannelli F; Guglielmelli P; Paoli C; Marone I; Cucci R; Coltro G; Sordi B; Albano F; Breccia M; De Stefano V; Finazzi G; Iurlo A; Martino B; Palandri F; Passamonti F; Siragusa S; Mannelli L; Fantoni D; Fazi P; Amadori S; Vignetti M; Barbui T; Vannucchi AM
    Am J Hematol; 2019 Sep; 94(9):E239-E242. PubMed ID: 31179561
    [No Abstract]   [Full Text] [Related]  

  • 7. JAK2 (and other genes) be nimble with MPN diagnosis, prognosis, and therapy.
    Ciboddo M; Mullally A
    Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):110-117. PubMed ID: 30504299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Looking for CALR mutations in familial myeloproliferative neoplasms.
    Maffioli M; Genoni A; Caramazza D; Mora B; Bussini A; Merli M; Giorgino T; Casalone R; Passamonti F
    Leukemia; 2014 Jun; 28(6):1357-60. PubMed ID: 24441291
    [No Abstract]   [Full Text] [Related]  

  • 9. From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms.
    Cazzola M; Kralovics R
    Blood; 2014 Jun; 123(24):3714-9. PubMed ID: 24786775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CALR mutations in a cohort of JAK2 V617F negative patients with suspected myeloproliferative neoplasms.
    Belcic Mikic T; Pajic T; Sever M
    Sci Rep; 2019 Dec; 9(1):19838. PubMed ID: 31882869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calreticulin gene mutations in myeloproliferative neoplasms without Janus kinase 2 mutations.
    Sun C; Zhang S; Li J
    Leuk Lymphoma; 2015 Jun; 56(6):1593-8. PubMed ID: 25115511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Laboratory practice guidelines for detecting and reporting JAK2 and MPL mutations in myeloproliferative neoplasms: a report of the Association for Molecular Pathology.
    Gong JZ; Cook JR; Greiner TC; Hedvat C; Hill CE; Lim MS; Longtine JA; Sabath D; Wang YL;
    J Mol Diagn; 2013 Nov; 15(6):733-44. PubMed ID: 23978506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations.
    Andrikovics H; Krahling T; Balassa K; Halm G; Bors A; Koszarska M; Batai A; Dolgos J; Csomor J; Egyed M; Sipos A; Remenyi P; Tordai A; Masszi T
    Haematologica; 2014 Jul; 99(7):1184-90. PubMed ID: 24895336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absence of JAK2V617F mutation in Chinese deep vein thrombosis patients without myeloproliferative neoplasms.
    Dong B; Zhang Y; Fu X; Wang G
    Thromb Res; 2012 May; 129(5):664-5. PubMed ID: 22197451
    [No Abstract]   [Full Text] [Related]  

  • 15. Editorial: the new age of clinical research in clonal hematopoiesis and myeloid malignancies.
    Guezguez B
    Curr Opin Hematol; 2021 Sep; 28(5):345-346. PubMed ID: 34261881
    [No Abstract]   [Full Text] [Related]  

  • 16. Molecular insights into regulation of JAK2 in myeloproliferative neoplasms.
    Silvennoinen O; Hubbard SR
    Blood; 2015 May; 125(22):3388-92. PubMed ID: 25824690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. JAK-STAT signaling in the therapeutic landscape of myeloproliferative neoplasms.
    O'Sullivan JM; Harrison CN
    Mol Cell Endocrinol; 2017 Aug; 451():71-79. PubMed ID: 28167129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Calreticulin gene mutations in the myeloproliferative neoplasms: Dameshek's other "myelostimulatory" factor.
    Stein BL; Platanias LC
    Leuk Lymphoma; 2015 Jun; 56(6):1573-4. PubMed ID: 25373510
    [No Abstract]   [Full Text] [Related]  

  • 19. JAK2V617F somatic mutation in the general population: myeloproliferative neoplasm development and progression rate.
    Nielsen C; Bojesen SE; Nordestgaard BG; Kofoed KF; Birgens HS
    Haematologica; 2014 Sep; 99(9):1448-55. PubMed ID: 24907356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical applications of molecular haematology: an overview.
    Bain BJ
    J Assoc Physicians India; 2007 Jul; 55():503-6. PubMed ID: 17907501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.